SVB Leerink Downgrades Principia Biopharma to Market Perform, Lowers Price Target to $100
SVB Leerink analyst Geoffrey Porges downgrades Principia Biopharma (NASDAQ:PRNB) from Outperform to Market Perform and lowers the price target from $112 to $100.